Alembic制药公司获得美国食品和药物管理局批准进行非专利癌症治疗,Nellarabine注射。 Alembic Pharmaceuticals receives USFDA approval for generic cancer treatment Nelarabine Injection.

Alembic制药公司获得美国食品与药物管理局对其非专利癌症治疗的最后批准,即Nellarabine注射,相当于Sandoz的Arranon注射。 Alembic Pharmaceuticals receives final USFDA approval for its generic cancer treatment, Nelarabine Injection, equivalent to Sandoz's Arranon Injection. T细胞急性淋巴球菌白血病和T细胞淋巴球菌淋巴瘤病的治疗对象为1岁及以上的成人和儿童。 The drug treats T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adults and children aged 1 year and older. 在2024年3月截止的一年中,Nellabine注射的市场规模估计为23M美元。 The market size for Nelarabine Injection is estimated at $23M for the year ending March 2024. 目前阿伦比克有211个经美国食品和药物管理局批准的简化新药物应用(ANDAs)。 Alembic now has 211 USFDA-approved abbreviated new drug applications (ANDAs).